R R

What Is Satralizumab?

Satralizumab-mwge is a prescription monoclonal antibody marketed under the brand name Enspryng. It blocks the interleukin-6 receptor and is approved to treat neuromyelitis optica spectrum disorder in adults who test positive for anti-aquaporin-4 antibodies. It is also approved for thyroid eye disease in adults, regardless of disease activity or duration. Satralizumab is administered by subcutaneous injection, with initial loading doses followed by maintenance treatment every four weeks. It reduces inflammatory signaling involved in these autoimmune conditions but does not permanently cure either disorder. Treatment requires screening for infections and monitoring for liver enzyme changes and low neutrophil counts.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Satralizumab?

Satralizumab-mwge is a prescription monoclonal antibody marketed under the brand name Enspryng. It blocks the interleukin-6 receptor and is approved to treat neuromyelitis optica spectrum disorder in adults who test positive for anti-aquaporin-4 antibodies. It is also approved for thyroid eye disease in adults, regardless of disease activity or duration. Satralizumab is administered by subcutaneous injection, with initial loading doses followed by maintenance treatment every four weeks. It reduces inflammatory signaling involved in these autoimmune conditions but does not permanently cure either disorder. Treatment requires screening for infections and monitoring for liver enzyme changes and low neutrophil counts.

read more about satralizumab ...

Copy this HTML:

Copy HTML Copied!

How Does Satralizumab Work?

Satralizumab binds to interleukin-6 receptors and blocks signaling by interleukin-6, an immune messenger involved in inflammation and antibody-related immune responses. In neuromyelitis optica spectrum disorder, abnormal immune activity involving aquaporin-4 antibodies damages parts of the central nervous system, particularly the optic nerves and spinal cord. Blocking IL-6 signaling can reduce the frequency of disease relapses. In thyroid eye disease, IL-6 signaling contributes to inflammation and tissue changes around the eyes. Satralizumab can reduce disease-related manifestations, including eye bulging in eligible patients. Its immune effects may also increase susceptibility to infections and alter laboratory findings.

What Conditions Does Satralizumab Treat?

Satralizumab is approved for adults with neuromyelitis optica spectrum disorder who are positive for anti-aquaporin-4 antibodies. This autoimmune condition can cause episodes of optic nerve inflammation, vision loss, spinal cord inflammation, weakness, and other neurological symptoms. Satralizumab is also approved for thyroid eye disease in adults, regardless of whether the disease is active or inactive or how long it has been present. Thyroid eye disease can cause eye bulging, double vision, swelling, and discomfort. The thyroid eye disease indication was added in October 2026. A specialist confirms the diagnosis and evaluates eye or neurological findings, infection history, and laboratory results before treatment.

How Is Satralizumab Administered?

Satralizumab is administered by subcutaneous injection using a prefilled syringe. For neuromyelitis optica spectrum disorder, the recommended dose is 120 mg at weeks zero, two, and four, followed by 120 mg every four weeks. For thyroid eye disease, patients weighing 40 kg to 100 kg receive 120 mg at weeks zero, two, and four, followed by 120 mg every four weeks. Patients weighing more than 100 kg receive 180 mg on the same loading and maintenance schedule. Safety and effectiveness for thyroid eye disease have not been established in patients weighing less than 40 kg. Patients or caregivers may administer injections after training. Hepatitis B, tuberculosis, and liver enzyme screening are required before treatment.

What Are the Side Effects and Warnings of Satralizumab?

Common adverse effects vary by indication and include upper respiratory infections, headache, joint pain, fatigue, nausea, and elevated liver enzymes. Serious risks include infections, liver injury, reduced neutrophil counts, and hypersensitivity reactions. Satralizumab is contraindicated in patients with active hepatitis B infection or active or untreated latent tuberculosis. Clinicians monitor liver enzymes and neutrophil counts during treatment and evaluate patients for infections before each dose. Live vaccines are not recommended during treatment. Persistent fever, severe cough, unusual weakness, yellowing of the skin, or signs of an allergic reaction require prompt medical evaluation. Patients with thyroid eye disease should continue appropriate ophthalmic monitoring.

Common Questions About Satralizumab

Is satralizumab the same as Enspryng?

Yes. Enspryng is the brand name for satralizumab-mwge, a monoclonal antibody that blocks interleukin-6 receptor signaling.

Can satralizumab treat thyroid eye disease?

Yes. In October 2026, the FDA approved Enspryng for thyroid eye disease in adults, regardless of disease activity or duration.

Can satralizumab treat neuromyelitis optica spectrum disorder?

Yes. Satralizumab is approved for adults with neuromyelitis optica spectrum disorder who test positive for anti-aquaporin-4 antibodies.

How often is satralizumab injected?

Treatment begins with injections at weeks zero, two, and four. Maintenance injections are given every four weeks, with the dose determined by indication and body weight.

References

DailyMed - ENSPRYNG (satralizumab-mwge) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64c156a4-9bad-4d45-a294-0733c141f47b. Date Accessed November 6, 2026.

ENSPRYNG Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761149s008lbl.pdf. Date Accessed November 6, 2026.

FDA Approves Genentech's Enspryng for Thyroid Eye Disease. Genentech. https://www.gene.com/media/press-releases/15137/2026-10-15/fda-approves-genentechs-enspryng-a-first. Date Accessed November 6, 2026.

Satralizumab-mwge Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620065.html. Date Accessed November 6, 2026.

Satralizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: A Randomised, Double-Blind, Multicentre, Placebo-Controlled Phase 3 Trial. The Lancet Neurology. https://doi.org/10.1016/S1474-4422(19)30419-8. Date Accessed November 6, 2026.